globes.co.il15h
Tal Zaks's Israeli startup targets rare genetic diseases
The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...
Boston biotech Atalanta raises $97M to bring CNS drugs into clinic
Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.
Sell Rating on Moderna Due to Uncertainties and Competitive Pressures
Leerink Partners analyst Mani Foroohar has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Invest with ...
Moderna (NASDAQ:MRNA) Price Target Cut to $50.00 by Analysts at Evercore ISI
Moderna (NASDAQ:MRNA – Free Report) had its price objective decreased by Evercore ISI from $60.00 to $50.00 in a research ...